Literature DB >> 20862616

Lentiviral vector-mediated gene transfer and RNA silencing technology in neuronal dysfunctions.

Jean-Luc Dreyer1.   

Abstract

Lentiviral-mediated gene transfer in vivo or in cultured mammalian neurons can be used to address a wide variety of biological questions, to design animals models for specific neurodegenerative pathologies, or to test potential therapeutic approaches in a variety of brain disorders. Lentiviruses can infect non-dividing cells, thereby allowing stable gene transfer in post-mitotic cells such as mature neurons. An important contribution has been the use of inducible vectors: the same animal can thus be used repeatedly in the doxycycline-on or -off state, providing a powerful mean for assessing the function of a gene candidate in a disorder within a specific neuronal circuit. Furthermore, lentivirus vectors provide a unique tool to integrate siRNA expression constructs with the aim to locally knockdown expression of a specific gene, enabling to assess the function of a gene in a very specific neuronal pathway. Lentiviral vector-mediated delivery of short hairpin RNA results in persistent knockdown of gene expression in the brain. Therefore, the use of lentiviruses for stable expression of siRNA in brain is a powerful aid to probe gene functions in vivo and for gene therapy of diseases of the central nervous system. In this chapter I review the applications of lentivirus-mediated gene transfer in the investigation of specific gene candidates involved in major brain disorders and neurodegenerative processes. Major applications have been in polyglutamine disorders, such as synucleinopathies and Parkinson's disease, or in investigating gene function in Huntington's disease, dystonia, or muscular dystrophy. Recently, lentivirus gene transfer has been an invaluable tool for evaluation of gene function in behavioral disorders such as drug addiction and attention-deficit hyperactivity disorder or in learning and cognition.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20862616     DOI: 10.1007/s12033-010-9334-x

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  179 in total

1.  Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS.

Authors:  Cédric Raoul; Toufik Abbas-Terki; Jean-Charles Bensadoun; Sandrine Guillot; Georg Haase; Jolanta Szulc; Christopher E Henderson; Patrick Aebischer
Journal:  Nat Med       Date:  2005-03-13       Impact factor: 53.440

2.  Neuropsychological analyses of comorbidity between reading disability and attention deficit hyperactivity disorder: in search of the common deficit.

Authors:  Erik G Willcutt; Bruce F Pennington; Richard K Olson; Nomita Chhabildas; Jacqueline Hulslander
Journal:  Dev Neuropsychol       Date:  2005       Impact factor: 2.253

3.  Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin.

Authors:  Alexandra Benchoua; Yaël Trioulier; Diana Zala; Marie-Claude Gaillard; Nathalie Lefort; Noelle Dufour; Frederic Saudou; Jean-Marc Elalouf; Etienne Hirsch; Philippe Hantraye; Nicole Déglon; Emmanuel Brouillet
Journal:  Mol Biol Cell       Date:  2006-02-01       Impact factor: 4.138

4.  Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector.

Authors:  Biljana Georgievska; Deniz Kirik; Carl Rosenblad; Cecilia Lundberg; Anders Björklund
Journal:  Neuroreport       Date:  2002-01-21       Impact factor: 1.837

5.  Extended polyglutamine repeats trigger a feedback loop involving the mitochondrial complex III, the proteasome and huntingtin aggregates.

Authors:  Hirokazu Fukui; Carlos T Moraes
Journal:  Hum Mol Genet       Date:  2007-03-13       Impact factor: 6.150

6.  Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells.

Authors:  Xiangmin Peng; Xiangmin M Peng; Roya Tehranian; Paula Dietrich; Leonidas Stefanis; Ruth G Perez
Journal:  J Cell Sci       Date:  2005-07-19       Impact factor: 5.285

7.  Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease.

Authors:  Sandro Alves; Etienne Régulier; Isabel Nascimento-Ferreira; Raymonde Hassig; Noelle Dufour; Arnulf Koeppen; Ana Luísa Carvalho; Sérgio Simões; Maria C Pedroso de Lima; Emmanuel Brouillet; Veronica Colomer Gould; Nicole Déglon; Luís Pereira de Almeida
Journal:  Hum Mol Genet       Date:  2008-04-01       Impact factor: 6.150

8.  Dysmyelination and reduced myelin basic protein gene expression by oligodendrocytes of SHP-1-deficient mice.

Authors:  Paul T Massa; Charlene Wu; Karen Fecenko-Tacka
Journal:  J Neurosci Res       Date:  2004-07-01       Impact factor: 4.164

9.  Alpha-synuclein in the nucleus accumbens induces changes in cocaine behaviour in rats.

Authors:  Frederic Boyer; Jean-Luc Dreyer
Journal:  Eur J Neurosci       Date:  2007-11       Impact factor: 3.386

10.  Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor.

Authors:  D L Choi-Lundberg; Q Lin; T Schallert; D Crippens; B L Davidson; Y N Chang; Y L Chiang; J Qian; L Bardwaj; M C Bohn
Journal:  Exp Neurol       Date:  1998-12       Impact factor: 5.330

View more
  12 in total

1.  Chitosan-Mangafodipir nanoparticles designed for intranasal delivery of siRNA and DNA to brain.

Authors:  Juan Sanchez-Ramos; Shijie Song; Xiaoyuan Kong; Parastou Foroutan; Gary Martinez; William Dominguez-Viqueria; Shyam Mohapatra; Subhra Mohapatra; Reka A Haraszti; Anastasia Khvorova; Neil Aronin; Vasyl Sava
Journal:  J Drug Deliv Sci Technol       Date:  2017-11-21       Impact factor: 3.981

2.  Intra-accumbal administration of shRNAs against CART peptides cause increases in body weight and cocaine-induced locomotor activity in rats.

Authors:  M O Job; J Licata; G W Hubert; M J Kuhar
Journal:  Brain Res       Date:  2012-09-11       Impact factor: 3.252

Review 3.  Antioxidant gene therapy against neuronal cell death.

Authors:  Juliana Navarro-Yepes; Laura Zavala-Flores; Annadurai Anandhan; Fang Wang; Maciej Skotak; Namas Chandra; Ming Li; Aglaia Pappa; Daniel Martinez-Fong; Luz Maria Del Razo; Betzabet Quintanilla-Vega; Rodrigo Franco
Journal:  Pharmacol Ther       Date:  2013-12-12       Impact factor: 12.310

Review 4.  Defining functional gene-circuit interfaces in the mouse nervous system.

Authors:  M E Soden; B B Gore; L S Zweifel
Journal:  Genes Brain Behav       Date:  2013-09-30       Impact factor: 3.449

Review 5.  Research advances in gene therapy approaches for the treatment of amyotrophic lateral sclerosis.

Authors:  Monica Nizzardo; Chiara Simone; Marianna Falcone; Giulietta Riboldi; Federica Rizzo; Francesca Magri; Nereo Bresolin; Giacomo P Comi; Stefania Corti
Journal:  Cell Mol Life Sci       Date:  2011-11-18       Impact factor: 9.261

Review 6.  Recent advances in lentiviral vectors for gene therapy.

Authors:  Xiaoyu Wang; Cuicui Ma; Roberto Rodríguez Labrada; Zhou Qin; Ting Xu; Zhiyao He; Yuquan Wei
Journal:  Sci China Life Sci       Date:  2021-07-14       Impact factor: 6.038

7.  Virally mediated gene manipulation in the adult CNS.

Authors:  Efrat Edry; Raphael Lamprecht; Shlomo Wagner; Kobi Rosenblum
Journal:  Front Mol Neurosci       Date:  2011-12-26       Impact factor: 5.639

Review 8.  Molecular Mechanisms and Biological Functions of siRNA.

Authors:  Hassan Dana; Ghanbar Mahmoodi Chalbatani; Habibollah Mahmoodzadeh; Rezvan Karimloo; Omid Rezaiean; Amirreza Moradzadeh; Narges Mehmandoost; Fateme Moazzen; Ali Mazraeh; Vahid Marmari; Mohammad Ebrahimi; Mohammad Menati Rashno; Saeid Jan Abadi; Elahe Gharagouzlo
Journal:  Int J Biomed Sci       Date:  2017-06

9.  An optimized method for high-titer lentivirus preparations without ultracentrifugation.

Authors:  Wei Jiang; Rui Hua; Mengping Wei; Chenhong Li; Zilong Qiu; Xiaofei Yang; Chen Zhang
Journal:  Sci Rep       Date:  2015-09-08       Impact factor: 4.379

Review 10.  Gene-based therapy of Parkinson's Disease: Translation from animal model to human clinical trial employing convection enhanced delivery.

Authors:  Gurwattan S Miranpuri; Lauren Kumbier; Angelica Hinchman; Dominic Schomberg; Anyi Wang; Hope Marshall; Ken Kubota; Chris Ross; Karl Sillay
Journal:  Ann Neurosci       Date:  2012-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.